Navigation Links
As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Date:3/26/2009

Twenty Percent of Surveyed MCO Pharmacy Directors Say They Will Alter Reimbursement of TNF-alpha Inhibitors for Juvenile Idiopathic Arthritis and Pediatric Crohn's Disease, According to a New Report from Decision Resources

WALTHAM, Mass., March 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 30 percent of surveyed rheumatologists have altered their prescription patterns for juvenile idiopathic arthritis and more than 10 percent have altered their prescription patterns for adult rheumatoid arthritis in response to the Food and Drug Administration's (FDA) investigation into the malignancy risk associated with TNF-alpha inhibitors.

In June 2008, the FDA launched an investigation into the malignancy risk associated with TNF-alpha inhibitors in pediatric and juvenile populations being treated for autoimmune diseases. Concerns were raised when 30 cases of cancer in pediatric and juvenile patients being treated for rheumatoid arthritis and Crohn's disease were reported between 1998 and 2008.

The new Physician & Payer Forum report entitled TNF-alpha Inhibitors in Pediatric Crohn's Disease and Juvenile Idiopathic Arthritis: How Will Physicians and Payers Balance Effective Treatments and Serious Safety Concerns? finds that, of the rheumatologists that have altered their prescription patterns for juvenile idiopathic arthritis, 71 percent say that they prescribe conventional disease-modifying antirheumatic drugs more frequently than they had in the past. Nearly 60 percent of surveyed gastroenterologists say they have altered their prescription patterns for pediatric Crohn's disease -- of these gastroenterologists, 42 percent indicate that they restrict TNF-alpha inhibitors to patients with more severe disease. Furthermore, 45 percent of gastroenterologists say that they have altered their prescribing habits in a
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cowden Associates Releases Eighth-Annual Employee Benefit Survey Results
2. China Medicine Announces Record Fourth Quarter and 2008 Results
3. Londons First Science-Based Cellulite Massage Guarantees Results for Londons Cellulite Sufferers
4. Boys Skin Care Range Finds Interesting Results
5. Surgical Care Affiliates Announces Investor Conference Call to Discuss 2008 Fourth Quarter and Year-End Results
6. Subtle Fillers Bring Breathtaking Results; The Neigel Center for Cosmetic and Laser Surgery Hosts Its March 27th Filler Day Specials!
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
8. Global Med Technologies(R), Inc. to Report Fourth Quarter and Year End Financial Results Today
9. Discovery may result in new test to determine predisposition to cancer
10. Cord Blood America Announces Results of Shareholder Special Meeting
11. Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... 29, 2015 , ... Healthpointe, one of Southern California’s leading ... MD., PhD into their world-class multidisciplinary team of physicians and specialists. Dr. ... Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons of Healthpointe, such as ...
(Date:6/29/2015)... ... 2015 , ... Mediaplanet has released the first edition of ... 12-page, glossy, full-color special section hit newsstands Friday, June 26th, and was distributed ... copies, with an estimated readership of 1.3 million. The digital component is being ...
(Date:6/29/2015)... NEW YORK, NEW YORK (PRWEB) , ... June ... ... obstructive sleep apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. ... and Drug Administration and is an alternative to continuous positive airway pressure (CPAP), ...
(Date:6/29/2015)... ... 2015 , ... National HealthCare Associates recently released a list ... 40-center nursing home group. Sixteen of their centers were rated “Best in Class” ... one or more customer service areas. Those centers received the prestigious “Customer Experience ...
(Date:6/29/2015)... ... 2015 , ... With Urgent Care Medicine now serving a vital role in ... Urgent Care Medicine and the Medical Society of Delaware to provide its latest professional ... health care professionals. , According to Matthew Bader, Exam Master CEO and President, “This ...
Breaking Medicine News(10 mins):Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3
... , HARBIN, China, Sept. 9 ... CKGT), a vertically integrated grower,developer, manufacturer and marketer of ... the Rodman and Renshaw Annual Global Investment,Conference to be ... Kangtai,Cactus Biotech will present as part of the Asia ...
... , , Obesity Experts ... , SILVER SPRING, Md., Sept. 9 ... to Overcome and Prevent (STOP) Obesity Alliance, and two former US Surgeons ... act on the inclusion of obesity as the largest and most urgent ...
... , CAMBRIDGE, Mass., Sept. 9 ... enterprise content compliance software solutions for ... Software-as-a-Service (SaaS) solution for managing clinical trial disclosure requirements. The ... a robust offering that automates compliance with global regulatory mandates ...
... , , TARRYTOWN, N.Y., Sept. 9 Bayer ... (R) 2 blood glucose meters -- Pink and Purple. , ... same unique easy to use(1) features as the original silver BREEZE2 ... the meter itself, so users do not have to handle individual ...
... They can get variety of illnesses from the sexually transmitted ... A U.S. health advisory committee on Wednesday will discuss whether ... transmitted human papillomavirus (HPV), for use in boys as well ... has asked the U.S. Food and Drug Administration to approve ...
... , , TITUSVILLE, ... to impact up to 20 percent of children(1) and 4 percent ... underdiagnosed: researchers estimate up to 20 percent of U.S. school-aged children ... but only 7.8 percent report receiving an ADHD diagnosis.(3) Meanwhile, it ...
Cached Medicine News:Health News:China Kangtai Cactus Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 11, 2009 2Health News:China Kangtai Cactus Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 11, 2009 3Health News:Obesity Driving America's Healthcare to a Tipping Point 2Health News:Obesity Driving America's Healthcare to a Tipping Point 3Health News:Obesity Driving America's Healthcare to a Tipping Point 4Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 2Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 3Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 4Health News:Bayer's BREEZE(R)2 Meter Available in Two New Vibrant Colors for a Limited Time 2Health News:FDA Panel Weighs Approving HPV Vaccine for Males 2Health News:FDA Panel Weighs Approving HPV Vaccine for Males 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 2Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 4Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 5
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: